Overview

* Outset Medical ( OM ) Q2 rev grows 15% yr/yr, driven by Tablo console sales

* Operating expenses down 30%, contributing to reduced net loss

* Co raises 2025 revenue guidance

Outlook

* Outset raises 2025 revenue guidance to $122 mln-$126 mln

* Company expects 2025 non-GAAP gross margin in high-30% range

* Outset anticipates using less than $50 mln cash in 2025

Result Drivers

* TABLO CONSOLE SALES - 25% increase in Tablo console revenue drove overall revenue growth, per CEO Leslie Trigg

* CONSUMABLES GROWTH - 17% increase in consumable revenue contributed to recurring revenue growth

* COST REDUCTION - Operating expenses declined nearly 30%, aiding in reduced net loss

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$18.54

Income mln

Q2 Gross 37.8%

Margin

Q2 Basic -$1.04

EPS

Q2 Gross $11.87

Profit mln

Q2 $28.73

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Outset Medical Inc ( OM ) is $23.00, about 38.7% above its August 5 closing price of $14.10

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)